Kromek Group PLC (AIM:KMK), a radiation and bio-detection technology leader, said it would report record revenues and positive earnings (EBITDA) as it told investors its financial performance had exceeded market expectations.
Kromek saw strong commercial momentum in the second half, driven by multi-year contracts in advanced imaging and CBRN detection. Improved gross margins and tight cost control have further boosted performance for the 12 months ended April 30.
The full-year results will be released in September 2024.